15 results
8-K
GLTO
Galecto Inc
9 Feb 22
Departure of Directors or Certain Officers
4:30pm
, Inc. (the “Company”) approved, effective as of February 3, 2022, the establishment of a Research and Development Committee of the Board (the “R&D Committee … for annual retainer compensation of the members and Chair of the R&D Committee. Each member of the R&D Committee will receive a member retainer of $7,500
8-K
EX-99.1
GLTO
Galecto Inc
8 Jan 21
Galecto Appoints Anne Prener to its Board of Directors
8:15am
. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio
DEF 14A
GLTO
Galecto Inc
14 Apr 21
Definitive proxy
7:00am
Scientific Officer and Vice President of R&D at Exiqon A/S, a Danish diagnostics company, which was acquired by QIAGEN in 2016. Earlier in his career … held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio. Dr
DRS
j8z tjzm6
2 Sep 20
Draft registration statement
12:00am
10-K
sj2n pfnuvu8dkoaam
29 Mar 21
Annual report
6:03am
PRE 14A
0z1ywz uc
16 Apr 24
Preliminary proxy
4:00pm
S-1/A
k6lj77r0
22 Oct 20
IPO registration (amended)
6:13am
424B4
2u8q xplqiw8kuwrncu
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1
7a0y1oww5pga4
7 Oct 20
IPO registration
5:01pm
- Prev
- 1
- Next